Souhaitez-vous accéder aux communiqués récents ?

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education...

MILTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- In celebration of its 10th consecutive year as the “Official Beer of Record Store Day,” Dogfish Head joins forces with Grateful Dead to launch a...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in...

Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology A

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by...

A report by Oceana reveals the dangers behind single-use plastic foam products. According to the report, plastic foam compromises our health and oceans.

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS® System in Focal Epilepsy at the 2025 AAN Annual Meeting

Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms...

After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 ...